Wedbush Securities Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 26.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,501 shares of the company’s stock after selling 12,007 shares during the period. Wedbush Securities Inc.’s holdings in Johnson & Johnson were worth $4,293,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Goodman Financial Corp purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $104,000. Stelac Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $108,000. Price Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $148,000. Roble Belko & Company Inc lifted its position in shares of Johnson & Johnson by 59.7% during the fourth quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock worth $163,000 after acquiring an additional 435 shares in the last quarter. Finally, Cerebellum GP LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $166,000. Institutional investors and hedge funds own 65.97% of the company’s stock.
Several research firms have issued reports on JNJ. Stifel Nicolaus dropped their target price on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Wednesday, April 18th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 target price on the stock in a research report on Wednesday, April 11th. Jefferies Financial Group set a $161.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, March 23rd. Citigroup dropped their target price on Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating on the stock in a research report on Monday, April 23rd. Finally, Deutsche Bank restated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 18th. Six investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $142.23.
Johnson & Johnson opened at $122.59 on Tuesday, according to MarketBeat. The firm has a market capitalization of $329.57 billion, a P/E ratio of 16.79, a PEG ratio of 1.88 and a beta of 0.73. The company has a current ratio of 1.58, a quick ratio of 1.25 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The firm’s revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.83 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were paid a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date of this dividend was Friday, May 25th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is currently 49.32%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.